HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2005.048389v1 51/10/1867    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (80) Citing Articles via Google Scholar Google Scholar Articles by Adams, L. A. Articles by Jeffrey, G. P. Search for Related Content PubMed PubMed Citation Articles by Adams, L. A. Articles by Jeffrey, G. P. Related Collections General Clinical Chemistry Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers

Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection

¹ Department of Gastroenterology and Hepatology, Sir Charles Gairdner Hospital, Perth, Australia.
² School of Population Health and ³ School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia.
⁴ PathCentre, Queen Elizabeth II Medical Centre, Perth, Australia.
⁵ Storr Liver Unit, Westmead Millennium Institute, Westmead Hospital, University of Sydney, Sydney, Australia.
⁶ AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia.

^aAddress correspondence to this author at: Department of Medicine and Pharmacology, The University of Western Australia, Nedlands, WA 6009, Australia. Fax 618-9346-3098; e-mail gjeffrey{at}cyllene.uwa.edu.au.

Background: Staging hepatic fibrosis by liver biopsy guides prognosis and treatment of hepatitis C, but is invasive and expensive. We sought to create an algorithm of serum markers that accurately and reliably predict liver fibrosis stage among hepatitis C patients.

Methods: Ten biochemical markers were measured at time of liver biopsy in 117 untreated hepatitis C patients (training set). Multivariate logistic regression and ROC curve analyses were used to create a predictive model for significant fibrosis (METAVIR F2, F3, and F4), advanced fibrosis (F3 and F4), and cirrhosis (F4). The model was validated in 104 patients from other institutions.

Results: A model (Hepascore) of bilirubin, -glutamyltransferase, hyaluronic acid, ₂-macroglobulin, age, and sex produced areas under the ROC curves (AUCs) of 0.85, 0.96, and 0.94 for significant fibrosis, advanced fibrosis, and cirrhosis, respectively. In the training set, a score 0.5 (range, 0.0–1.0) was 92% specific and 67% sensitive for significant fibrosis, a score <0.5 was 81% specific and 95% sensitive for advanced fibrosis, and a score <0.84 was 84% specific and 71% sensitive for cirrhosis. Among the validation set, the AUC for significant fibrosis, advanced fibrosis, and cirrhosis were 0.82, 0.90, and 0.89, respectively. A score 0.5 provided a specificity and sensitivity of 89% and 63% for significant fibrosis, whereas scores <0.5 had 74% specificity and 88% sensitivity for advanced fibrosis.

Conclusions: A model of 4 serum markers plus age and sex provides clinically useful information regarding different fibrosis stages among hepatitis C patients.

The following articles in journals at HighWire Press have cited this article:

				D. R. Dufour Assessment of Liver Fibrosis: Can Serum Become the Sample of Choice? Clin. Chem., October 1, 2005; 51(10): 1763 - 1764. [Full Text] [PDF]

eLetters: